Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Status: ...
People with myasthenia gravis have few treatment options and the unmet medical need is particularly great for people with antibodies against muscle-specific tyrosine kinase. Rystiggo has been shown to be effective in reducing the symptoms of myasthenia …